| Cancer Genomics and Diagnostics | Lifetime | 20 | US 14 | 99.92 |
| HER2/EGFR in Cancer Research | Lifetime | 26 | US 13 | 99.81 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 20 | US 13 | 99.76 |
| Breast Cancer Treatment Studies | Lifetime | 49 | US 27 | 99.81 |
| Advanced Breast Cancer Therapies | Lifetime | 29 | US 13 | 99.64 |
| Lung Cancer Treatments and Mutations | Lifetime | 136 | US 75 | 99.61 |
| Breast Lesions and Carcinomas | Lifetime | 54 | US 32 | 99.44 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 314 | US 194 | 99.38 |
| Peptidase Inhibition and Analysis | Lifetime | 186 | US 90 | 99.17 |
| Fibroblast Growth Factor Research | Lifetime | 46 | US 24 | 98.83 |
| Breast Implant and Reconstruction | Lifetime | 49 | US 39 | 99.02 |
| Cancer Research and Treatments | Lifetime | 174 | US 113 | 98.74 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 394 | US 211 | 99.09 |
| Cancer-related Molecular Pathways | Lifetime | 257 | US 153 | 99.01 |
| Cancer Diagnosis and Treatment | Lifetime | 231 | US 124 | 98.63 |
| Genetic factors in colorectal cancer | Lifetime | 282 | US 145 | 98.80 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 268 | US 92 | 98.77 |
| Cancer Cells and Metastasis | Lifetime | 321 | US 153 | 98.53 |
| Colorectal Cancer Treatments and Studies | Lifetime | 313 | US 148 | 99.01 |
| Cancer Treatment and Pharmacology | Lifetime | 366 | US 194 | 98.92 |
| BRCA gene mutations in cancer | Lifetime | 193 | US 106 | 98.40 |
| Genomics and Rare Diseases | Lifetime | 200 | US 109 | 98.09 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 817 | US 392 | 98.05 |
| Cancer Mechanisms and Therapy | Lifetime | 406 | US 182 | 95.96 |
| Lung Cancer Research Studies | Lifetime | 909 | US 373 | 97.09 |
| PARP inhibition in cancer therapy | Lifetime | 483 | US 228 | 94.76 |
| Melanoma and MAPK Pathways | Lifetime | 468 | US 244 | 95.48 |
| Health Literacy and Information Accessibility | Lifetime | 823 | US 417 | 89.20 |
| Genetics, Bioinformatics, and Biomedical Research | Lifetime | 912 | US 494 | 83.77 |
| Social Media in Health Education | Lifetime | 906 | US 476 | 81.18 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 5 | US 2 | 99.81 |
| Cancer Genomics and Diagnostics | 2021-2025 | 13 | US 7 | 99.81 |
| HER2/EGFR in Cancer Research | 2021-2025 | 11 | US 6 | 99.84 |
| Peptidase Inhibition and Analysis | 2021-2025 | 15 | US 5 | 99.53 |
| Fibroblast Growth Factor Research | 2021-2025 | 5 | US 3 | 99.18 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 85 | US 35 | 99.45 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 94 | US 17 | 98.98 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 47 | US 14 | 98.78 |
| Advanced Breast Cancer Therapies | 2021-2025 | 33 | US 13 | 99.37 |
| Cancer Treatment and Pharmacology | 2021-2025 | 57 | US 21 | 98.81 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 340 | US 134 | 98.69 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 109 | US 43 | 98.51 |
| Lung Cancer Research Studies | 2021-2025 | 119 | US 48 | 98.32 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 29 | US 19 | 94.96 |
| Genetic factors in colorectal cancer | 2021-2025 | 160 | US 71 | 96.16 |
| Cancer-related Molecular Pathways | 2021-2025 | 108 | US 48 | 93.31 |
| Melanoma and MAPK Pathways | 2021-2025 | 87 | US 27 | 95.20 |
| Cancer Research and Treatments | 2021-2025 | 187 | US 50 | 91.57 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 696 | US 296 | 93.29 |
| Cancer Diagnosis and Treatment | 2021-2025 | 282 | US 68 | 86.69 |
| PARP inhibition in cancer therapy | 2021-2025 | 351 | US 135 | 89.88 |
| Cancer Cells and Metastasis | 2021-2025 | 700 | US 182 | 86.53 |
| Cancer Mechanisms and Therapy | 2021-2025 | 424 | US 64 | 82.63 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 165 | US 32 | 76.71 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 886 | US 311 | 74.28 |
| Nuclear Structure and Function | 2021-2025 | 470 | US 173 | 63.52 |
